Medical Forum / Diseases and Disorders / Prostate Cancer / January 2007
Managing Bone Metastases and Pain
|
|
Thread rating:  |
J - 13 Jan 2007 10:43 GMT <http://www.prostatecancerfoundation.org/site/c.itIWK2OSG/b.47320/k.3A88/Managing _Bone_Metastases_and_Pain.htm>
Managing Bone Metastases and Pain
Prostate cancer cells that spread to the bone are known as prostate cancer bone metastases (not bone cancer). Once they settle in the bone, the cancer cells begin to interfere with the normal health and strength of the bones, often leading to bone pain, fracture, or other complications that can significantly impair ones health.
Early detection of bone metastases can help to determine the best treatment strategy, and can help to ward off complications caused by the metastases.
In addition, because men with prostate cancer bone metastases often experience painful episodes, pain management and improving quality of life is an important part of all treatment strategies for men with bone metastases.
Treating Metastases
An important part of prostate cancer bone metastases management is maintaining adequate calcium and vitamin D levels and exercising regularly. Even though none of these are treatments for bone metastases, they will all help to maintain strong bones and help to minimize bone loss and osteoporosis, which can make treating bone metastases more challenging.
Radiation Therapy Targeting Bone Metastases Men who experience pain from a bone metastasis will often be treated with radiation targeted directly to the metastasis. This will kill the prostate cancer cells and relieve the pain. (Note that radiation therapy used to treat bone metastases is completely unrelated to radiation therapy that might have been used earlier in prostate cancer treatment.)
External beam radiation therapy uses x-rays to kill the cancer cells that have settled in the bones. This type of treatment, sometimes referred to as spot radiation, is mapped out and planned very precisely by the radiation oncologist to ensure that the x-rays are targeting the metastasis and are not causing damage to the surrounding bone and muscle tissue.
Radiopharmaceuticals, or radioactive drugs, are injected into the body through a vein and settle in the bone metastases, at which point they release radiation to the local area and kill the cancer cells. The two drugs used for this procedure, samarium (Quadramet) and strontium (Metastron), are sometimes used in combination with chemotherapy.
Bone-Targeting Agents (Bisphosphonates) Under normal circumstances, bone cells are destroyed and created at a constant rate. Increasing the activity of osteoblasts, cells that form new bone cells, ultimately results in an overgrowth of bone tissue; increasing the activity of osteoclasts, cells that destroy bone cells, ultimately results in porous, brittle bone tissue. In men with prostate cancer bone metastases, both of these processes occur at faster than normal rates, leading to both an overgrowth of bone tissue and weakened and brittle bones. The combination of these two processes makes the bones unstable, and therefore prone to fracture.
Bisphosphonates are drugs that are designed to help reset the balance in the bone between bone growth and bone destruction. Zoledronic acid (Zometa) is a bisphosphonate given intravenously that can delay the onset of complications associated with prostate cancer bone metastases and relieve pain. It is typically given once every three weeks as a 15-minute infusion.
Other bisphosphonates are sometimes used in men with prostate cancer to prevent or slow bone loss while taking hormone therapy. These drugs, alendronate (Fosamax) and risedronate (Actonel), are given in pill form, and are also used to counteract the bone loss of osteoporosis in postmenopausal women or in women who are taking hormone therapy for breast cancer.
Anticipating Complications
Treatment for prostate cancer bone metastases has three goals: to slow disease progression, to relieve pain, and, perhaps most importantly, to avoid the complications that stem from the weakened bone caused by the metastases.
Bone that is weakened by metastases is more prone to fracture, and because the metastases often grow around the lower back and upper legs, hip fractures tend to be most common. Vigilant monitoring for fractures is common; less commonly, surgery might be considered to stabilize bones at risk. This procedure can improve the chances of not fracturing the bones, and therefore help to stave off other complications down the road.
The most significant complication from bone metastases is spinal cord compression. A weakening of a vertebra by a prostate cancer bone metastasis can result in the bones of the spinal column collapsing one on top of the other, compressing the spinal cord housed within the bones as well as the nerves that run out from it.
Cord compression associated with metastatic prostate cancer can cause severe nerve damage, and possibly paralysis, if not managed immediately. Therefore, additional medications, such as steroids, might be used for men at high risk for a spinal cord compression, and surgery to stabilize the weakened bones might be considered. MRI scans can also be used to better visualize the health of the spinal column and to detect early any problems that might occur.
The symptoms of spinal cord compression are often similar to those seen with many other medical problems. For example, because bone metastases typically occur around the lower back and upper legs, compression of the spinal cord at that point can cause back pain, leg pain or weakness, or loss of bladder or bowel control. It is therefore important to recognize and address any symptoms as soon as possible. The earlier new fractures or a spinal cord compression is detected, the easier it is to treat.
Managing Pain
There are three general rules of pain management to always keep in mind.
1. Dont try to be too tough or act "macho". Untreated pain takes a toll on the body, forcing it to expend a lot of energy fighting it.
2. There might be a very simple solution to the pain. Some very simple and easy to take medications might be enough to ease the pain.
3. Dont worry about becoming addicted to pain medication. The most common reason that doctors are afraid to prescribe strong pain medications and that people are afraid to take them is fear of addiction. But thats mostly because people dont understand the differences between addiction, physical dependence, and tolerance.
Addiction is a psychological and behavioral syndrome in which there is continual or increasing use of a drug despite negative physical, psychological, or social consequences. Taking pain medications to feel healthier and stronger would seem to be exactly the opposite of addictive behavior.
Someone who is physically dependent upon a drug will not be able to cope with its loss if it is stopped or if the dose is lowered too rapidly, and symptoms of withdrawal will be seen. This is why doses of strong pain medications are usually tapered, or gradually lowered, before stopping, giving the body a chance to adjust to its loss.
After using a certain drug for a long period of time, the body will become tolerant to it, to the point where the drug is no longer effective. Slowly increasing the doses over time can help to avoid the onset of tolerance, but thats only a temporary measure, and youll likely have to switch to a medication that works in a slightly different manner before you can find relief.
Note that every pain medication, like all other medications, has its own set of side effects. Constipation is the most common side effect of pain medication use; other side effects can include nausea and vomiting, sleepiness, and confusion. Knowing which side effects to expect can help decide how best to deal with them.
I.P. Freely - 13 Jan 2007 19:35 GMT > <http://www.prostatecancerfoundation.org/site/c.itIWK2OSG/b.47320/k.3A88/Managing _Bone_Metastases_and_Pain.htm> > > Managing Bone Metastases and Pain Excellent summation, but . . . what next? Does the pain become unmanageable, and if so, what do we do about *that*?
I.P.
RML - 13 Jan 2007 20:02 GMT My uncle passed from PCa this past summer, and was in hospice. At the end, he had a Fentanyl patch, and was receiving liquid morphine. Although he experienced visual hallucinations and poor ability to keep his eyes open, he did not seem in pain.
>Excellent summation, but . . . what next? Does the pain become >unmanageable, and if so, what do we do about *that*? > >I.P. MAS - 14 Jan 2007 06:30 GMT I know that this is a terrible disease and a fear of bones mets is overwhelming. Excellent summation, however, I do want to point out that I did not do or experience any of what you wrote and what others before you wrote (maybe my day is coming, only God knows.)
In March of 1994, I had two mets to T3 and L2. After a clinical trial of chemo for six months, the mets are gone and replaced with new bone growth. My mets disappeared with the January 1995 scan. I have had seven scand since then and still am "all clear."
Gourd Dancer
> <http://www.prostatecancerfoundation.org/site/c.itIWK2OSG/b.47320/k.3A88/Managing _Bone_Metastases_and_Pain.htm> > [quoted text clipped - 145 lines] > sleepiness, and confusion. Knowing which side effects to expect can help > decide how best to deal with them. Just - 21 Jan 2007 17:10 GMT Gourd,
Which chemo did you take in the clinical trial?
Just
>I know that this is a terrible disease and a fear of bones mets is >overwhelming. Excellent summation, however, I do want to point out that I [quoted text clipped - 157 lines] >> sleepiness, and confusion. Knowing which side effects to expect can help >> decide how best to deal with them.
 Signature Posted via a free Usenet account from http://www.teranews.com
MAS - 22 Jan 2007 06:09 GMT Here are two publications describing the trial.
Trial of Chemotherapy plus Hormonal Therapy as Initial Treatment for Unresectable / Metastatic Adenocarcinoma of the Prostate H. Henary, R.J. Amato; The Methodist Hospital/The Methodist Hospital Research Institute/Genitourinary Program, Houston, TX
Background: Chemotherapy is a setting of hormone refractory prostate cancer has shown palliative benefit especially with substantial PSA decline strongly suggesting that disease modifying potential exists. Recently, chemotherapy is beginning to show a survival advantage. The stage is set for chemotherapy given earlier in a disease course. As a working hypothesis, we suspect that the transformation from an androgen-dependent to an androgen-independent phenotype is mediated by the expansion of an androgen-independent clone already present at the time of androgen deprivation. If this model is correct, then it would be desirable to bring treatment to bear on the androgen-independent component when the corresponding tumor burden is minimal. Thus, we view the androgen-independent component as analogous to "microscopic residual" or "micro-metastatic" disease for which adjuvant chemotherapy has shown to be effective in other contexts. Methods: Each course of chemotherapy lasts for 8 weeks. Patients were treated in weeks 1, 3, and 5 with doxorubicin 20 mg/m2 as a 24-hour intravenous infusion on the first day of every week in combination with ketoconazole 400 mg orally 3 times a day daily for 7 days. In weeks 2, 4, and 6, treatment consisted of paclitaxel 100 mg/m2 intravenously on the first day of every week in combination with estramustine 280 mg orally 3 times a day for 7 days. After completion of 3 courses of chemotherapy, hormone management [medical castration plus casodex (at the completion of chemotherapy)] is initiated at the start of chemotherapy and for a total of 24 months. Results: Nineteen men have been enrolled with a median age of 63 (48-76). Fifty percent of the men had no prior local therapy, while the other 50% either failed surgery, radiation therapy, or surgery plus radiation therapy. Fifty-nine percent of the men had Gleason 7, 12%/8, 24%/9, and 5%/10. Thirty-five patients presented with bone metastasis and 50% presented with nodal involvement. The median PSA reduction to date has been 95.6%. Conclusion: Enrollment is ongoing. Further information regarding PSA response, associated radiographic response, and toxicity will be presented.
Trial of Chemotherapy (CHT) Plus Hormonal Therapy An Initial Treatment for Prostate Cancer (PC) Maushumi Karediy, Tung Shu, Muhammed Khan and Robert Amato The Methodist Hospital Research Institute, Genitourinary Oncology Center Houston, Texas Background: The delivery of CHT in a setting of androgen-independent (AI) PC has demonstrated: survival benefit associated with a PSA decline and tolerable toxicity, thus strongly suggesting that disease modifying potential exists. Preclinical data supports the benefit of simultaneous CHT and androgen deprivation (AD). The stage is set for CHT to be given earlier in men with PC. Data suggests a transformation from an androgen-dependent to an AI phenotype is mediated by the expansion of an AI clone already present at the time of AD. If this model is correct, it would be feasible to bring CHT up front when the corresponding tumor burden is minimal. Methods: A course of CHT is defined as 8 weeks (6 on/2 off). The therapy consists of weeks 1, 3, and 5 with adriamycin 20 mg/m2 as a 24 hour intravenous infusion on the first day of every week in combination with ketoconazole 400 mg orally 3 times a day, daily for 7 days. Weeks 2, 4, and 6 treatment consisted of docetaxel 35 mg/m2 intravenously over 1 hour on the first day of every week in combination with estramustine 280 mg orally 3 times a day, daily for 7 days. Hormone therapy, GnRH antagonist, is initiated within the first 6 months of starting CHT. Following the completion of 3 courses of CHT, the addition of casodex occurs. Hormone management then continues for a total of 24 months, and then is discontinued. Patients (pts) are followed every 12 weeks with a PSA, testosterone and routine laboratory evaluation. For those men who have had a PSA recurrence, hormone therapy will be reinitiated. Results: 31 men have been enrolled to date. 61% percent of the men had no prior local therapy, while the other 39% had surgery, radiation therapy or both. 3% had a gleason 6, 45%/7, 26%/8, 23%/9 and 3%/10. 64% of the men presented with bone and/or nodal metastases. Baseline median PSA was 12.7 (1.1-1065.5). The median PSA reduction to date has been 96% with associated nodal and bone scan improvement. Conclusion: Enrollment is ongoing. Information regarding PSA response, radiographic outcome, toxicity and results of men who are discontinuing hormones will be presented.
> Gourd, > [quoted text clipped - 190 lines] >>> sleepiness, and confusion. Knowing which side effects to expect can help >>> decide how best to deal with them. J - 22 Jan 2007 09:02 GMT > I know that this is a terrible disease and a fear of bones mets is > overwhelming. Excellent summation, however, I do want to point out that I [quoted text clipped - 7 lines] > > Gourd Dancer Sounds like you had arthritis (inflammation). Chemotherapy has anti-inflammatory properties. You'd have known by now, if it was bone mets, because chemotherapy doesn't stop bone mets from spreading. Think about it. If it did, Lori's husband and many others would be alive today. J
kh - 22 Jan 2007 13:17 GMT > > I know that this is a terrible disease and a fear of bones mets is > > overwhelming. Excellent summation, however, I do want to point out that I [quoted text clipped - 5 lines] > > My mets disappeared with the January 1995 scan. I have had seven scand since > > then and still am "all clear." He means 2004 and 2005.
> > Gourd Dancer > > Sounds like you had arthritis (inflammation). > Chemotherapy has anti-inflammatory properties. > You'd have known by now, if it was bone mets, because chemotherapy doesn't stop bone mets from spreading. Think > about it. If it did, Lori's husband and many others would be alive today. This may be different. MAS posted his PSA log and it shows a shockingly active cancer, doubling in 30 days. Chemotherapy doesn't stop the typical prostate cancer because it is so slow growing.
His mets were like a raging fire compared to typical cancers. Maybe, just maybe, this variation can be treated with chemotherapy.
Donno.
-kh
MAS - 25 Jan 2007 05:30 GMT They were mets....
>> I know that this is a terrible disease and a fear of bones mets is >> overwhelming. Excellent summation, however, I do want to point out that I [quoted text clipped - 16 lines] > about it. If it did, Lori's husband and many others would be alive today. > J dave perry - 21 Jan 2007 21:47 GMT > 3. Don't worry about becoming addicted to pain medication. The most common > reason that doctors are afraid to prescribe strong pain medications and > that people are afraid to take them is fear of addiction. But that's > mostly because people don't understand the differences between addiction, > physical dependence, and tolerance. Another reason is that the DEA monitors the amounts of narcotic-like drugs prescribed by each physician. If a doctor goes over his allotment - a bit like claiming too many deductions on your income tax for your income status - the doc has to explain (is audited). Some doctors don't give a damn and prescribe what's needed, others are more cautious sometimes to the detriment of their patients.
Always remember, there is no pain that can't be subdued by sufficient medication. The question is how conscious does the patient want to be? Also, patients and their families have to be told that large amounts of these meds can hasten death again causing doctors to be cautious since they can, and often are, sued for killing a patient. As far as addiction is concerned, that should be the last concern of anyone in or approaching hospice-like conditions. If I may be insensitive for a moment, it's like a condemned man requesting that his last meal before execution be low sodium because he has to watch his blood pressure. Dave Perry
I.P. Freely - 21 Jan 2007 22:28 GMT > there is no pain that can't be subdued by sufficient > medication. The question is how conscious does the patient want to be? > Also, patients and their families have to be told that large amounts > of these meds can hasten death again causing doctors to be cautious > since they can, and often are, sued for killing a patient. Exactly why it's critical that terminal cancer patients -- and anyone who could get hit by a bus tomorrow -- should have filed copies of their terminal care preferences (hell, DEMANDS) with those doctors, the hospital administration, the pt's family and lawyer . . . and maybe the local bus lines. Without that level of exposure and legality, many physicians lean towards liability risks and Hippocratic oaths rather than pt's wishes.
I want my wife, and if necessary her lawyer, standing by my bedside waving my properly executed power of attorney, advanced directive, and names and addresses of that doctor's children (that part's a joke, folks) in my doc's face over my pain-wracked body. And when the doc says, "large amounts of these meds can hasten death", I want both wife and lawyer shouting in unison, " _*DUH!!!*_; What's your point?"
Unless, of course, my lawyer's hand is on my wife's a.s and I'm just sleeping off a day of heavy windsurfing.
I.P.
LarryS - 22 Jan 2007 02:17 GMT [snip]
> Unless, of course, my lawyer's hand is on my wife's a.s and I'm just > sleeping off a day of heavy windsurfing. ROTFLMAOWTIME (Rolling on the floor laughing my a.s off, with tears in my eyes)
|
|
|